Dermatology’s growing focus on skin longevity demands clear definitions, validated outcomes, and rigorous evidence beyond anti-aging claims.
|Articles|March 1, 2002
Trial compares responses to BTX-A, BTX-B
New Orleans - Results of a preliminary, double-blind, parallel group study demonstrate the efficacy of botulinum toxin type A (BTX-A, Botox) 20 units and botulinum toxin type B (BTX-B, Myobloc) 1,000 and 2,000 units for correcting deep glabellar furrows.
Advertisement
Advertisement
Related to this article
Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Advertisement
Advertisement
Trending on Dermatology Times
1
Lutikizumab Meets Primary End Point in Phase 3 HS Trial
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
4
Nonsteroidal Topicals Guide Special-Site Psoriasis Treatment Decisions
5